[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3357513T3 - Kompozycja farmaceutyczna i jej zastosowanie - Google Patents

Kompozycja farmaceutyczna i jej zastosowanie

Info

Publication number
PL3357513T3
PL3357513T3 PL16850363.9T PL16850363T PL3357513T3 PL 3357513 T3 PL3357513 T3 PL 3357513T3 PL 16850363 T PL16850363 T PL 16850363T PL 3357513 T3 PL3357513 T3 PL 3357513T3
Authority
PL
Poland
Prior art keywords
application
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL16850363.9T
Other languages
English (en)
Inventor
Chuansheng Ge
Baisong Liao
Wen-Cherng Lee
Original Assignee
Kangpu Biopharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangpu Biopharmaceuticals, Ltd. filed Critical Kangpu Biopharmaceuticals, Ltd.
Publication of PL3357513T3 publication Critical patent/PL3357513T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL16850363.9T 2015-09-29 2016-09-28 Kompozycja farmaceutyczna i jej zastosowanie PL3357513T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510631654 2015-09-29
PCT/CN2016/100642 WO2017054739A1 (zh) 2015-09-29 2016-09-28 一种药物组合物及其应用

Publications (1)

Publication Number Publication Date
PL3357513T3 true PL3357513T3 (pl) 2024-04-02

Family

ID=58418383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16850363.9T PL3357513T3 (pl) 2015-09-29 2016-09-28 Kompozycja farmaceutyczna i jej zastosowanie

Country Status (16)

Country Link
US (3) US20180271849A1 (pl)
EP (1) EP3357513B1 (pl)
JP (1) JP6633744B2 (pl)
KR (1) KR102053556B1 (pl)
CN (1) CN106551934B (pl)
AU (1) AU2016332236B2 (pl)
BR (1) BR112018006025B1 (pl)
CA (1) CA3000547C (pl)
DK (1) DK3357513T3 (pl)
ES (1) ES2963446T3 (pl)
HK (1) HK1251153A1 (pl)
NZ (1) NZ742001A (pl)
PL (1) PL3357513T3 (pl)
RU (1) RU2705576C2 (pl)
WO (1) WO2017054739A1 (pl)
ZA (1) ZA201802125B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10941382B2 (en) * 2016-01-29 2021-03-09 Kyoto University Platelet production promoter and method of producing platelets using same
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806719B2 (en) * 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
RU2731535C1 (ru) * 2016-12-16 2020-09-04 Канпу Биофармасьютикалз, Лтд. Комбинация, ее применение и способ лечения
AU2017202864B2 (en) * 2017-02-13 2020-04-23 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
FI3784663T3 (fi) * 2018-04-23 2023-10-06 Celgene Corp Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
WO2020205608A1 (en) * 2019-03-29 2020-10-08 Emory University Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
JP2023522040A (ja) * 2020-04-17 2023-05-26 エッサ ファーマ,インコーポレイテッド N末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
CN113440533B (zh) * 2021-07-01 2022-02-01 江南大学 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
CN113855797B (zh) * 2021-11-19 2023-11-10 安徽科技学院 一种兽用免疫疫苗的稀释剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20140011774A1 (en) * 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
PL2066656T3 (pl) * 2006-09-26 2012-09-28 Celgene Corp 5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe
KR20160079147A (ko) * 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제
WO2010062656A2 (en) * 2008-10-28 2010-06-03 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
WO2010093434A1 (en) * 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
US8716314B2 (en) * 2009-02-11 2014-05-06 Celgene Corporation Isotopologues of thalidomide
WO2011050962A1 (en) * 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
AU2011215877C1 (en) 2010-02-11 2017-01-19 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2014236597A1 (en) * 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
JP6546997B2 (ja) * 2014-10-30 2019-07-17 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用

Also Published As

Publication number Publication date
HK1251153A1 (zh) 2019-01-25
AU2016332236A8 (en) 2018-06-14
EP3357513A4 (en) 2018-08-29
EP3357513A1 (en) 2018-08-08
JP2018530555A (ja) 2018-10-18
BR112018006025B1 (pt) 2023-12-05
KR102053556B1 (ko) 2020-01-08
US20210113545A1 (en) 2021-04-22
CN106551934A (zh) 2017-04-05
US20240173312A1 (en) 2024-05-30
ZA201802125B (en) 2022-11-30
JP6633744B2 (ja) 2020-01-22
AU2016332236B2 (en) 2019-04-11
NZ742001A (en) 2019-06-28
ES2963446T3 (es) 2024-03-27
EP3357513B1 (en) 2023-10-25
RU2018115037A3 (pl) 2019-10-25
US20180271849A1 (en) 2018-09-27
CA3000547A1 (en) 2017-04-06
BR112018006025A2 (pt) 2018-10-09
AU2016332236A1 (en) 2018-05-17
RU2705576C2 (ru) 2019-11-08
CA3000547C (en) 2021-03-23
DK3357513T3 (da) 2023-11-27
KR20180054840A (ko) 2018-05-24
WO2017054739A1 (zh) 2017-04-06
RU2018115037A (ru) 2019-10-25
CN106551934B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
HK1251153A1 (zh) 一種藥物組合物及其應用
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
IL269061A (en) A pharmaceutical preparation containing Selexifag
HK1258704A1 (zh) 藥物組合物和塗料
HK1252026A1 (zh) 藥物組合及其應用
IL252967A0 (en) Pharmaceutical preparations containing plasminogen and their uses
HK1245086A1 (zh) 處方藥物組成及其製備和使用
ZA201703398B (en) Pharmaceutical composition and methods
HK1245085A1 (zh) 處方藥物組成及其製備和使用
IL263040A (en) Pharmaceutical composition comprising eteplirsen
EP3388085A4 (en) PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF
HK1245113A1 (zh) 藥物組合物及其用途
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
HK1250915A1 (zh) 組合物和其用途
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
GB201519644D0 (en) Therapy and pharmaceutical composition
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses